SARS-CoV-2-IN-119

SARS-CoV-2-IN-119 (Compound A28) is a SARS-CoV-2 fusion inhibitor that effectively impedes Omicron virus entry. It exhibits inhibitory activity against pOmicron (BA.2.86.1) and wild-type Omicron with EC50 values of 1.95 μM and 1.08 μM, respectively. Additionally, SARS-CoV-2-IN-119 shows antiviral activity against wild-type SARS-CoV-2 and other variant strains, including pseudotyped Delta SARS-CoV-2, pOmicron (BA.4), and (KP.3). This compound functions by directly disrupting Omicron S2-mediated viral membrane fusion, thereby preventing Omicron virus entry into host cells. SARS-CoV-2-IN-119 is applicable for COVID-19 research.